Vanguard Group Inc. Increases Stock Holdings in Sarepta Therapeutics, Inc. $SRPT

Vanguard Group Inc. lifted its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 18.1% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 10,817,446 shares of the biotechnology company’s stock after acquiring an additional 1,657,267 shares during the quarter. Vanguard Group Inc. owned approximately 0.11% of Sarepta Therapeutics worth $208,452,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the stock. State of Michigan Retirement System raised its stake in Sarepta Therapeutics by 3.1% during the 2nd quarter. State of Michigan Retirement System now owns 23,600 shares of the biotechnology company’s stock worth $404,000 after acquiring an additional 700 shares in the last quarter. Arizona State Retirement System boosted its stake in Sarepta Therapeutics by 2.8% in the third quarter. Arizona State Retirement System now owns 26,165 shares of the biotechnology company’s stock valued at $504,000 after acquiring an additional 717 shares in the last quarter. Thrivent Financial for Lutherans grew its holdings in shares of Sarepta Therapeutics by 3.3% during the second quarter. Thrivent Financial for Lutherans now owns 23,140 shares of the biotechnology company’s stock worth $396,000 after purchasing an additional 744 shares during the last quarter. New York Life Investment Management LLC increased its position in shares of Sarepta Therapeutics by 10.0% during the second quarter. New York Life Investment Management LLC now owns 10,623 shares of the biotechnology company’s stock worth $182,000 after purchasing an additional 966 shares in the last quarter. Finally, AlphaQuest LLC lifted its holdings in shares of Sarepta Therapeutics by 118.3% in the 3rd quarter. AlphaQuest LLC now owns 2,561 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 1,388 shares during the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Sarepta Therapeutics news, COO Ian Michael Estepan sold 13,187 shares of Sarepta Therapeutics stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $22.31, for a total value of $294,201.97. Following the sale, the chief operating officer directly owned 193,300 shares in the company, valued at approximately $4,312,523. The trade was a 6.39% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 7.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on SRPT shares. Mizuho upgraded Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $19.00 to $26.00 in a research note on Wednesday, November 5th. Barclays started coverage on shares of Sarepta Therapeutics in a report on Wednesday, January 28th. They issued an “equal weight” rating and a $20.00 target price on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Sarepta Therapeutics in a research report on Monday, December 29th. Wedbush upped their target price on shares of Sarepta Therapeutics from $32.00 to $34.00 and gave the company an “outperform” rating in a report on Friday, January 23rd. Finally, Guggenheim lowered their price target on Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Nine research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $33.56.

Sarepta Therapeutics Price Performance

SRPT stock opened at $16.76 on Monday. The stock has a 50-day moving average price of $20.43 and a two-hundred day moving average price of $20.22. Sarepta Therapeutics, Inc. has a 1 year low of $10.41 and a 1 year high of $108.48. The stock has a market cap of $1.76 billion, a PE ratio of -1.99, a price-to-earnings-growth ratio of 0.27 and a beta of 0.42. The company has a current ratio of 2.32, a quick ratio of 1.48 and a debt-to-equity ratio of 0.73.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) EPS for the quarter, missing the consensus estimate of ($0.87) by ($2.71). The firm had revenue of $442.93 million during the quarter, compared to the consensus estimate of $390.95 million. Sarepta Therapeutics had a negative net margin of 38.34% and a negative return on equity of 50.74%. The company’s revenue was down 32.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.90 EPS. Equities analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Key Sarepta Therapeutics News

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Revenue beat estimates in Q4 ($442.9M vs. ~$391M consensus), which partially offsets earnings weakness and suggests underlying commercial traction outside the challenged product. Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates
• Positive Sentiment: Wells Fargo kept an “overweight” rating on SRPT, implying continued analyst conviction in the story despite lowering its price target to $38 (from $45), signaling potential upside from current levels. Wells Fargo Lowers Price Target
• Neutral Sentiment: Sarepta expanded non-market PR and community programs — opening applications for the Route 79 Duchenne scholarship — which supports brand and patient-community relations but is unlikely to move near-term valuation. Sarepta Announces Route 79 Scholarship
• Neutral Sentiment: Sarepta plans to present long-term and safety data at the upcoming MDA conference — data releases could be material but timing and contents are uncertain. Sarepta to Present Long-Term Data at MDA
• Negative Sentiment: Large Q4 EPS miss: reported EPS was far worse than consensus (reported loss −$3.58 vs. est. −$0.87), driven by a steep decline in ELEVIDYS sales and a wider net loss, increasing short-term revenue and margin uncertainty. Sarepta Q4 Earnings Report
• Negative Sentiment: CEO Douglas Ingram announced he will retire by year-end (or upon his replacement), introducing leadership transition risk at a sensitive time for product recovery and strategy execution. Reuters: Sarepta CEO Ingram to Retire
• Negative Sentiment: Institutional selling: AXQ Capital materially trimmed its SRPT stake (large percentage reduction), which can add selling pressure and signal reduced conviction among some holders. AXQ Capital Lowers Position in Sarepta

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.